EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of proton-pump inhibitor and anti-CD3 F(ab’)2 for islet neogenesis and immune modulation in type 1 diabetes

Tung-Yun Wu iD, Che-Yi Chen, Michael Chen, Chang-Hung Wang, An-Pei Kao, Kai-Hung Wang, Kuo-Hsiang Chuang iD, Shyr-Yi Lin

Immunotherapy Advances · 31.12.2025 · 6 (1)

DOI: 10.1093/immadv/ltag017 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Immunotherapy Advances, online erschienen am 22.07.2026. Verfasst von Tung-Yun Wu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan. Die Arbeit nennt 55 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes, National Science and Technology Council, Jin-Lung-Yuan Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Type 1 diabetes (T1D) is an autoimmune disease characterized by T cell–mediated destruction of pancreatic β cells. Current insulin therapy does not address autoimmune pathology or restore endogenous β-cell function, highlighting the need for disease-modifying strategies.

Methods

We developed a combination therapy integrating a proton pump inhibitor (PPI; omeprazole) with a non–Fc-binding anti-CD3 F(ab’)2 antibody fragment (anti-CD3 F(ab’)2) to concurrently promote β-cell neogenesis and modulate autoimmune T-cell responses. T1D was induced in nonobese diabetic (NOD) mice using a cyclophosphamide-accelerated protocol (CY-NOD). Following hyperglycemia onset, mice received combination treatment and were evaluated by blood glucose monitoring, flow cytometric analysis of T-cell populations, and assessment of pancreatic β-cell function. Therapeutic efficacy was further examined in spontaneous-onset NOD mice.

Results

Combination therapy restored normoglycemia without exogenous insulin, reduced lymphocytic infiltration in pancreatic islets, and preserved endogenous insulin secretion. Treatment decreased pathogenic CD4+ and CD8+ T cells, increased regulatory T cells, and enhanced transforming growth factor-β expression. Comparable and durable glycemic control was observed in spontaneous-onset NOD mice.

Conclusions

Concurrent modulation of β-cell function and autoimmune immunity achieved sustained glycemic control in T1D models. The use of clinically approved agents supports the translational potential of this non–insulin-dependent therapeutic strategy.

Schlagwörter

Stichwörter der Autor:innen

anti-CD3 F(ab’)2autoimmune diseaseislet neogenesisproton-pump inhibitortype 1 diabetes

Autor:innen und Institutionen

  • Graduate Institute of Pharmacognosy, Taipei Medical University, Taipei, Taiwan.
  • Ph.D. Program in Clinical Drug Development of Herbal Medicine, Taipei Medical University, Taipei, Taiwan.
  • Cytoarm Co., Ltd, Taipei, Taiwan.
  • Department of Obstetrics and Gynecology, Kuo General Hospital, Tainan City, Taiwan.
  • Center for Reproductive Medicine, Kuo General Hospital, Tainan, Taiwan.
  • Master Program for Clinical Pharmacogenomics and Pharmacoproteomics, Taipei Medical University, Taipei, Taiwan.

ORCID-Profile: Tung-Yun Wu, Kuo-Hsiang Chuang

Förderung

  • National Health Research Institutes
  • National Science and Technology Council
  • Jin-Lung-Yuan Foundation

Zitieren

APA

Wu, T. Y., Chen, C. Y., Chen, M., Wang, C. H., Kao, A. P., Wang, K. H., Chuang, K. H., & Lin, S. Y. (2025). Combination of proton-pump inhibitor and anti-CD3 F(ab’)2 for islet neogenesis and immune modulation in type 1 diabetes. Immunotherapy Advances, 6(1). https://doi.org/10.1093/immadv/ltag017

Vancouver

Wu TY, Chen CY, Chen M, Wang CH, Kao AP, Wang KH, et al. Combination of proton-pump inhibitor and anti-CD3 F(ab’)2 for islet neogenesis and immune modulation in type 1 diabetes. Immunotherapy Advances. 2025;6(1). doi:10.1093/immadv/ltag017

BibTeX
@article{Wu2025,
  author = {Wu, Tung-Yun and Chen, Che-Yi and Chen, Michael and Wang, Chang-Hung and Kao, An-Pei and Wang, Kai-Hung and Chuang, Kuo-Hsiang and Lin, Shyr-Yi},
  title = {Combination of proton-pump inhibitor and anti-CD3 F(ab’)2 for islet neogenesis and immune modulation in type 1 diabetes},
  journal = {Immunotherapy Advances},
  year = {2025},
  volume = {6},
  number = {1},
  doi = {10.1093/immadv/ltag017}
}
Kostenlos starten →